Loading...

STADA Arzneimittel

SWX:SAZ
Snowflake Description

Excellent balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SAZ
SWX
€5B
Market Cap
  1. Home
  2. CH
  3. Pharmaceuticals & Biotech
Company description

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
SAZ Share Price and Events
7 Day Returns
0%
SWX:SAZ
-0.7%
CH Pharmaceuticals
0.4%
CH Market
1 Year Returns
-6.1%
SWX:SAZ
23%
CH Pharmaceuticals
6.1%
CH Market
SAZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
STADA Arzneimittel (SAZ) 0% 0% 0% -6.1% 136.5% -
CH Pharmaceuticals -0.7% 3.6% 10.3% 23% 20.3% 17.5%
CH Market 0.4% 3.2% 10.9% 6.1% 18.1% 15.1%
1 Year Return vs Industry and Market
  • SAZ underperformed the Pharmaceuticals industry which returned 23% over the past year.
  • SAZ underperformed the Market in Switzerland which returned 6.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is STADA Arzneimittel undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of STADA Arzneimittel to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for STADA Arzneimittel.

SWX:SAZ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.7%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:SAZ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.731 (1 + (1- 30%) (27.62%))
0.915
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.91
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.915 * 5.96%)
8.73%

Discounted Cash Flow Calculation for SWX:SAZ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for STADA Arzneimittel is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

SWX:SAZ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.73%)
2019 114.30 Est @ -7.94% 105.12
2020 109.07 Est @ -4.57% 92.26
2021 106.65 Est @ -2.22% 82.98
2022 106.04 Est @ -0.57% 75.88
2023 106.66 Est @ 0.58% 70.20
2024 108.14 Est @ 1.39% 65.46
2025 110.26 Est @ 1.96% 61.39
2026 112.85 Est @ 2.35% 57.79
2027 115.81 Est @ 2.63% 54.55
2028 119.08 Est @ 2.82% 51.59
Present value of next 10 years cash flows €717.21
SWX:SAZ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €119.08 × (1 + 3.28%) ÷ (8.73% – 3.28%)
€2,256.25
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,256.25 ÷ (1 + 8.73%)10
€977.38
SWX:SAZ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €717.21 + €977.38
€1,694.59
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,694.59 / 62.26
€27.22
SWX:SAZ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:SAZ represents 1.11354x of MUN:SAZ
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.11354x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (EUR) x Listing Adjustment Factor
= € 27.22 x 1.11354
CHF30.31
Value per share (CHF) From above. CHF30.31
Current discount Discount to share price of CHF92.98
= -1 x (CHF92.98 - CHF30.31) / CHF30.31
-206.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of STADA Arzneimittel is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for STADA Arzneimittel's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are STADA Arzneimittel's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:SAZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €4.93
MUN:SAZ Share Price ** MUN (2019-01-10) in EUR €83.5
Europe Pharmaceuticals Industry PE Ratio Median Figure of 44 Publicly-Listed Pharmaceuticals Companies 22.49x
Switzerland Market PE Ratio Median Figure of 176 Publicly-Listed Companies 18.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of STADA Arzneimittel.

SWX:SAZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= MUN:SAZ Share Price ÷ EPS (both in EUR)

= 83.5 ÷ 4.93

16.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • STADA Arzneimittel is good value based on earnings compared to the Europe Pharmaceuticals industry average.
  • STADA Arzneimittel is good value based on earnings compared to the Switzerland market.
Price based on expected Growth
Does STADA Arzneimittel's expected growth come at a high price?
Raw Data
SWX:SAZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-8.2%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 36 Publicly-Listed Pharmaceuticals Companies 1.81x
Switzerland Market PEG Ratio Median Figure of 122 Publicly-Listed Companies 2.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for STADA Arzneimittel, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on STADA Arzneimittel's assets?
Raw Data
SWX:SAZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €16.99
MUN:SAZ Share Price * MUN (2019-01-10) in EUR €83.5
Switzerland Pharmaceuticals Industry PB Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 2.81x
Switzerland Market PB Ratio Median Figure of 210 Publicly-Listed Companies 1.64x
SWX:SAZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= MUN:SAZ Share Price ÷ Book Value per Share (both in EUR)

= 83.5 ÷ 16.99

4.92x

* Primary Listing of STADA Arzneimittel.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • STADA Arzneimittel is overvalued based on assets compared to the CH Pharmaceuticals industry average.
X
Value checks
We assess STADA Arzneimittel's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. STADA Arzneimittel has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is STADA Arzneimittel expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover STADA Arzneimittel, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is STADA Arzneimittel expected to grow at an attractive rate?
  • STADA Arzneimittel's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 3.3%.
Growth vs Market Checks
  • STADA Arzneimittel's earnings are expected to decrease over the next 1-3 years, this is below the Switzerland market average.
  • Unable to compare STADA Arzneimittel's revenue growth to the Switzerland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SWX:SAZ Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:SAZ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -8.2%
Switzerland Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 4.9%
Switzerland Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 2.2%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 8.7%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:SAZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:SAZ Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
SWX:SAZ Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 2,331 320 307
2018-09-30 2,313 298 216
2018-06-30 2,308 268 160
2018-03-31 2,306 284 93
2017-12-31 2,314 263 85
2017-09-30 2,307 347 80
2017-06-30 2,248 310 94
2017-03-31 2,208 346 105
2016-12-31 2,139 334 86
2016-09-30 2,123 372 121
2016-06-30 2,124 384 139
2016-03-31 2,126 312 119

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • STADA Arzneimittel's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if STADA Arzneimittel is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:SAZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from STADA Arzneimittel Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:SAZ Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
SWX:SAZ Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 4.93
2018-09-30 3.47
2018-06-30 2.58
2018-03-31 1.49
2017-12-31 1.37
2017-09-30 1.29
2017-06-30 1.51
2017-03-31 1.69
2016-12-31 1.38
2016-09-30 1.94
2016-06-30 2.23
2016-03-31 1.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if STADA Arzneimittel will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess STADA Arzneimittel's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
STADA Arzneimittel has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has STADA Arzneimittel performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare STADA Arzneimittel's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • STADA Arzneimittel's year on year earnings growth rate has been positive over the past 5 years.
  • STADA Arzneimittel's 1-year earnings growth exceeds its 5-year average (259.7% vs 14.8%)
  • STADA Arzneimittel's earnings growth has exceeded the Europe Pharmaceuticals industry average in the past year (259.7% vs 13.5%).
Earnings and Revenue History
STADA Arzneimittel's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from STADA Arzneimittel Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:SAZ Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,330.82 306.93 723.13 72.26
2018-09-30 2,312.86 216.34 718.60 70.44
2018-06-30 2,308.15 160.36 715.59 69.18
2018-03-31 2,305.72 92.84 708.67 67.15
2017-12-31 2,313.93 85.32 715.09 67.47
2017-09-30 2,306.85 80.29 707.58 69.39
2017-06-30 2,247.79 94.17 690.55 67.28
2017-03-31 2,208.41 105.49 688.03 66.79
2016-12-31 2,139.22 85.90 672.08 65.11
2016-09-30 2,123.29 120.73 662.62 63.49
2016-06-30 2,123.91 138.79 661.48 62.41
2016-03-31 2,126.08 118.80 668.41 63.69
2015-12-31 2,115.13 110.40 662.02 64.99
2015-09-30 2,113.06 55.41 653.37 60.46
2015-06-30 2,085.34 51.43 632.59 61.24
2015-03-31 2,041.00 50.79 616.42 59.22
2014-12-31 2,062.25 64.56 613.16 56.91
2014-09-30 2,060.41 130.32 614.70 60.17
2014-06-30 2,039.89 121.53 640.32 57.27
2014-03-31 2,038.12 121.49 645.76 56.06
2013-12-31 2,003.91 121.43 643.92 55.35
2013-09-30 1,931.33 108.27 635.75 53.06
2013-06-30 1,919.12 104.96 621.27 53.72
2013-03-31 1,867.39 101.95 610.53 52.16
2012-12-31 1,837.54 86.47 601.99 52.10
2012-09-30 1,796.19 96.91 577.26 52.30
2012-06-30 1,770.89 14.13 563.52 52.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst STADA Arzneimittel has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
  • STADA Arzneimittel used its assets more efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.
  • STADA Arzneimittel has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess STADA Arzneimittel's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
STADA Arzneimittel has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is STADA Arzneimittel's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up STADA Arzneimittel's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • STADA Arzneimittel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • STADA Arzneimittel's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of STADA Arzneimittel's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from STADA Arzneimittel Company Filings, last reported 3 months ago.

SWX:SAZ Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,177.99 1,427.34 354.27
2018-09-30 1,163.59 1,488.97 430.93
2018-06-30 1,146.57 1,412.55 260.40
2018-03-31 1,056.12 889.13 281.73
2017-12-31 1,006.41 1,316.16 252.31
2017-09-30 1,069.31 1,435.10 397.38
2017-06-30 1,102.70 1,431.68 350.03
2017-03-31 1,117.67 1,429.31 361.90
2016-12-31 1,047.11 1,489.49 381.78
2016-09-30 1,024.17 1,577.39 438.52
2016-06-30 1,061.60 1,596.85 442.04
2016-03-31 1,014.14 1,395.50 250.59
2015-12-31 1,018.53 1,361.10 187.19
2015-09-30 1,017.69 1,431.66 181.04
2015-06-30 1,046.85 1,505.64 187.61
2015-03-31 1,028.03 1,438.57 185.46
2014-12-31 903.34 1,494.78 214.91
2014-09-30 1,053.29 1,530.61 183.50
2014-06-30 1,031.65 1,590.11 197.17
2014-03-31 1,016.75 1,570.57 224.95
2013-12-31 1,010.10 1,441.52 161.67
2013-09-30 954.78 1,529.38 176.41
2013-06-30 940.54 1,522.54 353.61
2013-03-31 969.22 1,256.88 129.75
2012-12-31 910.32 1,280.94 118.60
2012-09-30 894.54 1,336.35 108.86
2012-06-30 860.01 1,329.80 99.23
  • STADA Arzneimittel's level of debt (121.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (142.8% vs 121.2% today).
  • Debt is well covered by operating cash flow (22.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 10.5x coverage).
X
Financial health checks
We assess STADA Arzneimittel's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. STADA Arzneimittel has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is STADA Arzneimittel's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from STADA Arzneimittel dividends.
If you bought CHF2,000 of STADA Arzneimittel shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate STADA Arzneimittel's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate STADA Arzneimittel's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:SAZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 31 Stocks 3.2%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 167 Stocks 3.1%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.9%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:SAZ Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
SWX:SAZ Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-20 0.000 0.000
2018-11-28 0.110 0.135

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as STADA Arzneimittel has not reported any payouts.
  • Unable to verify if STADA Arzneimittel's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of STADA Arzneimittel's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as STADA Arzneimittel has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess STADA Arzneimittel's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can STADA Arzneimittel afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. STADA Arzneimittel has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of STADA Arzneimittel's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Goldschmidt
AGE 54
TENURE AS CEO 0.6 years
CEO Bio

Mr. Peter Goldschmidt serves as the President of Sandoz Inc. Mr. Goldschmidt serves as Head of North American Operations at Sandoz International GmbH and has been its President of Sandoz US since July 2013. Mr. Goldschmidt serves as Chairman of the Executive Board and Chief Executive Officer at STADA Arzneimittel Aktiengesellschaft since September 1, 2018. Mr. Goldschmidt served as Head of Commercial Operations for North America at Sandoz International GmbH. Mr. Goldschmidt served as the Head of Central and Eastern Europe at Sandoz International GmbH and Novartis AG (Formerly Sandoz AG) since January 2009. Mr. Goldschmidt joined Sandoz from Novartis where he served as Country Group Head for the Philippines, Singapore and Indonesia. He joined Novartis Group in 1990 and held a number of positions in marketing, sales, strategic planning and organizational development. Mr. Goldschmidt served as Country President for Novartis Healthcare in the Philippines since July 2007. Mr. Goldschmidt served as Head of Marketing Sales of Novartis Germany from 2001 to 2007. He served as Head of Marketing for Novartis in Sweden from 1999 to 2001. Mr. Goldschmidt served as Chairman of Supervisory Board at Lek Pharmaceuticals d.d. since June 2009. He serves as Director of Association for Accessible Medicines. He served as a Member of the Supervisory Board at GfK SE since December 2, 2016 until April 13, 2017. Mr. Goldschmidt is a graduate in Politics and Economic Geography at the University of Muenster in Germany and holds a Masters degree in Sociology. He has completed Post-graduate studies at the London Business School, UK, the Harvard Business School and Stanford Business School in the US.

CEO Compensation
  • Insufficient data for Peter to compare compensation growth.
  • Insufficient data for Peter to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the STADA Arzneimittel management team in years:

1.6
Average Tenure
53.5
Average Age
  • The average tenure for the STADA Arzneimittel management team is less than 2 years, this suggests a new team.
Management Team

Mark Keatley

TITLE
CFO & Member of Executive Board
COMPENSATION
€1M
AGE
61
TENURE
1.6 yrs

Peter Goldschmidt

TITLE
Chairman of the Executive Board & CEO
AGE
54
TENURE
0.6 yrs

Miguel Fernandez

TITLE
CTO & Member of Executive Board
AGE
53
TENURE
0.8 yrs

Sebastian Kramer-Bach

TITLE
Executive Vice President of Corporate Communication
AGE
43
TENURE
2.3 yrs

Kay Reubelt

TITLE
Director of Investor Relations
TENURE
2.6 yrs
Board of Directors Tenure

Average tenure and age of the STADA Arzneimittel board of directors in years:

1.6
Average Tenure
59.5
Average Age
  • The average tenure for the STADA Arzneimittel board of directors is less than 3 years, this suggests a new board.
Board of Directors

Günter von Au

TITLE
Chairman of Supervisory Board
COMPENSATION
€73K
AGE
67
TENURE
1.6 yrs

Jens Steegers

TITLE
Deputy Chairman of Supervisory Board
COMPENSATION
€168K
AGE
38

Thomas Meyer

TITLE
Chairman of Advisory Board
AGE
76

Michael Siefke

TITLE
Member of Supervisory Board
AGE
51
TENURE
1.6 yrs

Frank-R. Leu

TITLE
Deputy Chairman of Advisory Board

Wolfgang Berger

TITLE
Member of Advisory Board

Rika Aschenbrenner

TITLE
Member of Advisory Board

Reimar von Kolczynski

TITLE
Member of Advisory Board

Halil Duru

TITLE
Member of Supervisory Board
COMPENSATION
€91K
AGE
58

Eric Cornut

TITLE
Member of Supervisory Board
COMPENSATION
€110K
AGE
61
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess STADA Arzneimittel's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. STADA Arzneimittel has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux. The Branded Products segment offers APO-Go for Parkinson’s disease; Grippostad for cold; Aqualor for rhinitis/soare throat; Snup for rhinitis; and Vitaprost for prostate disease. It serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.

Details
Name: STADA Arzneimittel Aktiengesellschaft
SAZ
Exchange: SWX
Founded: 1895
€5,829,247,261
62,258,167
Website: http://www.stada.de
Address: STADA Arzneimittel Aktiengesellschaft
Stadastrasse 2-18,
Bad Vilbel,
61118,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
MUN SAZ Common Shares Boerse Muenchen DE EUR 18. Feb 1998
OTCPK STDA.F Common Shares Pink Sheets LLC US USD 18. Feb 1998
LSE 0OM4 Common Shares London Stock Exchange GB EUR 18. Feb 1998
SWX SAZ Common Shares SIX Swiss Exchange CH CHF 18. Feb 1998
OTCPK STDA.Y ADR Pink Sheets LLC US USD 03. Dec 2008
Number of employees
Current staff
Staff numbers
10,416
STADA Arzneimittel employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/09 21:32
End of day share price update: 2019/01/10 00:00
Last estimates confirmation: 2018/03/08
Last earnings filing: 2019/03/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.